---
url: https://www.servicesaustralia.gov.au/gastrointestinal-stromal-tumour
title: Gastrointestinal stromal tumour - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:40:38.955Z
source: servicesaustralia.gov.au
---
# Gastrointestinal stromal tumour

The PBS subsidises imatinib, ripretinib and sunitinib for patients with gastrointestinal stromal tumour.

## on this page

-   [Patient eligibility](#a1)
-   [Authority applications](#a2)
-   [More information](#a3)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with imatinib, ripretinib and sunitinib under the _National Health Act 1953_, section 85 for patients with gastrointestinal stromal tumour (GIST).

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=jrrab7f28xtjycras12yiccu) on the PBS website outlines the restrictions for prescribing imatinib, ripretinib and sunitinib.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised imatinib to treat resected primary GIST and high risk of recurrence, or imatinib and ripretinib to treat metastatic or unresectable malignant GIST can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

Applications for initial authority approval to prescribe PBS-subsidised sunitinib to treat metastatic or unresectable malignant GIST can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [gastrointestinal stromal tumour - sunitinib - initial authority application form](/pb096?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised ripretinib to treat metastatic or unresectable malignant GIST can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

Continuing PBS-subsidised treatment with imatinib to treat resected primary GIST with high risk of recurrence, or imatinib and sunitinib to treat metastatic or unresectable malignant GIST is Authority Required (Streamlined). You don’t need prior authority approval from us for the listed quantities and repeats.

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
